<DOC>
	<DOCNO>NCT01735955</DOCNO>
	<brief_summary>The purpose study allow continue use nilotinib patient nilotinib treatment Novartis-sponsored , Oncology Clinical Development &amp; Medical Affairs ( CD &amp; MA ) study benefit treatment judge investigator</brief_summary>
	<brief_title>Study Allow Access Nilotinib Patients Who Are Nilotinib Treatment Novartis-sponsored Study</brief_title>
	<detailed_description />
	<criteria>Patient currently enrol Novartissponsored , Oncology Clinical Development &amp; Medical Affairs study receive nilotinib fulfil requirement parent study Patient currently benefit treatment nilotinib , determine investigator Patient demonstrate compliance , assess investigator , parent study protocol requirement Willingness ability comply schedule visit , treatment plan study procedure Written inform consent obtain prior enrol rollover study Patient permanently discontinue nilotinib treatment parent study due unacceptable toxicity , noncompliance study procedure , withdrawal consent reason Patient participate Novartis sponsor combination trial nilotinib dispense combination another study medication patient still receive combination therapy Patients currently receive treatment medication potential prolong QT interval induce Torsade de Pointes treatment either safely discontinue least one week prior nilotinib treatment switch different medication prior start nilotinib treatment duration study Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hcG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception study 30 day final dose nilotinib .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tasigna</keyword>
	<keyword>CML</keyword>
	<keyword>GIST</keyword>
	<keyword>nilotinib</keyword>
</DOC>